IP has supported the fastest development and scale-up of safe and effective vaccines in history, with 13.9 billion COVID-19 vaccines produced to date. The IP framework has provided the basis for more than 380 voluntary partnerships for COVID-19 vaccines to be set up in record time, 88% of which involve technology transfer¹.

Today’s decision sends a dangerous signal not only to the pharmaceutical industry but to all innovative sectors. Dismantling the very framework that has brought solutions to tackle COVID-19 and facilitated the unprecedented number of partnerships, voluntary licensing, and knowledge-sharing taking place during this pandemic can have ripple effects for the future.

Thomas Cueni, IFPMA Director-General, said: “The conversations on an intellectual property waiver have been challenging from the beginning, with disregard to evidence and facts. The decision is a disservice to the scientists that left no stone unturned and undermines manufacturing partnerships on every continent. The single biggest factor affecting vaccine scarcity is not intellectual property, but trade. This has not been fully addressed by the World Trade Organization”.

About IFPMA

IFPMA (https://www.ifpma.org/) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

https://www.ifpma.org/resource-centre/research-based-biopharmaceutical-industry-on-the-trips-waiver-discussions-at-wto-ministerial-conference-mc12